Advertisement

Topics

BioLight Life Sciences (BOLT) - Promising Eye-D VS-101 Phase I/IIa data

05:56 EDT 7 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - BioLight Life Sciences: BioLight reported positive results from a 77-patient US Phase I/IIa study on Eye-D VS-101, being developed as an extended-dose platform for treating glaucoma. We have raised our estimate for the candidate’s probability of commercial success to 30% (from 20%), which, with other adjustments, leads to an increase in our rNPV valuation to NIS121.6-135.7m.
ISIN: IL0010952237

Original Article: BioLight Life Sciences (BOLT) - Promising Eye-D VS-101 Phase I/IIa data

NEXT ARTICLE

More From BioPortfolio on "BioLight Life Sciences (BOLT) - Promising Eye-D VS-101 Phase I/IIa data"

Quick Search
Advertisement
 

Relevant Topics

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...